Acute Myeloid Leukemia (non-APL) · line 2 · Enasidenib monotherapy for R/R IDH2-mutated AML

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-ENASIDENIB-AML`

ID	`IND-AML-2L-IDH2-ENASIDENIB`
Type	Indication
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-ESMO-AML-2020` `SRC-NCCN-AML-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for R/R IDH2-mutated AML. Bridge-to-alloHCT intent dominant. Ukraine access constraint dominant (not registered, EU CHMP negative). Algorithm wiring deferred — not yet routed by ALGO-AML-2L step 5 (which currently routes IDH1/IDH2 to ven+aza with MDT note); restructure required to swap step 5 to IND-AML-2L-IDH2-ENASIDENIB; out of chunk scope. Bibliographic record SRC-IDHENTIFY and SRC-AG221-AML-001 bibliographic records are available; source-to-claim mapping requires dual clinical sign-off.

Used By

Algorithms

ALGO-AML-2L - ALGO-AML-2L